Pharmacy Times July 29, 2024
Benzgalantamine (Zunveyl; Alpha Cognition) is a cholinesterase inhibitor indicated for the treatment of mild-to-moderate dementia in adults.
This is a developing story.
The FDA has approved benzgalantamine (Zunveyl; Alpha Cognition), a cholinesterase inhibitor, to treat mild-to-moderate dementia associated with Alzheimer disease (AD) in adults. The novel oral therapy is designed to eliminate drug absorption in the gastrointestinal tract, which addresses tolerability concerns associated with other AD medications.
“The approval of [benzgalantamine] is a pivotal moment in the fight against Alzheimer disease as it is only the second oral AD treatment to be approved...
Today's Sponsors
Today's Sponsor